Emergent BioSolutions Announces Shelf-Life Extension For NARCAN Nasal Spray In Canada From 36-Months To 48-Months

7/22/24 8:07:45 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $EBS alert in real time by email

The extension to a four-year shelf-life helps improve naloxone access as communities continue to grapple with the growing opioid epidemic; product with the extended shelf life has officially begun shipping

WINNIPEG, Manitoba, July 22, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions announced the shelf-life extension for NARCAN® Nasal Spray from three years (36 months) to four years (48 months) to all newly manufactured product. The update makes NARCAN® Nasal Spray the only 4 mg, intranasal naloxone spray in Canada with this extended expiration date. The Health Canada notification to extend NARCAN® Nasal Spray's shelf-life was completed on February 2, 2024.

Get the next $EBS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EBS

Date	Price Target	Rating	Analyst
8/22/2024	$16.00	Buy	Rodman & Renshaw
3/7/2024	$5.00	Hold → Buy	The Benchmark Company
11/20/2023		Underweight	JP Morgan
8/29/2023		Buy → Hold	The Benchmark Company
4/10/2023	$22.00	Hold → Buy	The Benchmark Company
3/17/2023	$23.00 → $9.00	Neutral → Underweight	JP Morgan
11/10/2022		Buy → Hold	The Benchmark Company
4/29/2022		Overweight → Neutral	Cantor Fitzgerald

More analyst ratings

$EBS
Market Insights

Live Market Insights

Emergent BioSolutions Announces Shelf-Life Extension For NARCAN Nasal Spray In Canada From 36-Months To 48-Months
The extension to a four-year shelf-life helps improve naloxone access as communities continue to grapple with the growing opioid epidemic; product with the extended shelf life has officially begun shipping WINNIPEG, Manitoba, July 22, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions announced the shelf-life extension for NARCAN® Nasal Spray from three years (36 months) to four years (48 months) to all newly manufactured product. The update makes NARCAN® Nasal Spray the only 4 mg, intranasal naloxone spray in Canada with this extended expiration date. The Health Canada notification to extend NARCAN® Nasal Spray's shelf-life was completed on February 2, 2024.
7/22/24 8:07:45 AM ET
$EBS
Biotechnology: Pharmaceutical Preparations
Health Care
How To Earn $500 A Month From American Express Stock Ahead Of Q2 Earnings
American Express Company (NYSE:AXP) will release its second-quarter financial results, before the opening bell on Friday, July 19. Analysts expect the New York-based company to report quarterly earnings at $3.25 per share, up from $2.89 per share in the year-ago period. American Express will post revenue of $16.59 billion, compared to $15.05 billion a year earlier, according to data from Benzinga Pro. On July 16, Compass Point analyst David Rochester initiated coverage on American Express with a Neutral rating and announced a price target of $260. With the recent buzz around American Express, some investors may be eyeing potential gains from the company's dividends, too. As of now,
7/18/24 8:25:50 AM ET
$AXP
$EBS
Finance: Consumer Services
Finance
Biotechnology: Pharmaceutical Preparations
Health Care
How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q2 Earnings
Johnson & Johnson (NYSE:JNJ) will release its second-quarter financial results, before the opening bell on Wednesday, July 17. Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.70 per share, up from $2.56 per share in the year-ago period. Johnson & Johnson is expected to post revenue of $22.29 billion, compared to $25.53 billion a year earlier, according to data from Benzinga Pro. Emergent BioSolutions Inc (NYSE:EBS), through its subsidiary Emergent Manufacturing Operations Baltimore, recently reached a settlement with Janssen Pharmaceuticals, Inc., a branch of Johnson & Johnson, resolving disputes related to the manufacturing of Johnson & J
7/16/24 8:06:35 AM ET
$EBS
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care

Emergent BioSolutions Reports Third Quarter 2024 Financial Results
Third Quarter 2024 Total Revenues of $293.8 million, increase of 9% versus prior yearThird Quarter 2024 Net Income of $114.8 million, increase of 144% versus prior yearThird Quarter 2024 Adjusted EBITDA of $105.3 million, increase of 432% versus prior yearRaises FY 2024 guidance GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the third quarter ended September 30, 2024. "Through disciplined execution and steady, measurable progress, Emergent's financial position is the strongest it has been since 2021 as evidenced by our favorable third-quarter results," said CEO Joe Papa. "We have successfully improved effici
11/6/24 4:05:00 PM ET
$EBS
Biotechnology: Pharmaceutical Preparations
Health Care
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
GAITHERSBURG, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, November 6, 2024, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2024, recent business developments, and financial outlook for full year 2024. Webcast & Conference Call InformationParticipants can access the conference call live via webcast. To join via telephone, please use the following dial-in details: U.S. / New York: +1-646-968-2525U.S. & Canada (Toll Free): +1-888-596-4144Conference ID: 5259189 A replay of the call can be accessed from the Investors page of Emergent's website. About Emergent BioSolutionsAt Emergent
10/23/24 7:30:55 AM ET
$EBS
Biotechnology: Pharmaceutical Preparations
Health Care
Emergent BioSolutions Reports Second Quarter 2024 Financial Results
Second Quarter 2024 Total Revenues of $254.7 million, above the prior guidance rangeSecond Quarter 2024 Net Loss of $283.1 million and Adjusted EBITDA of $(10.1) millionUpdates FY 2024 guidance GAITHERSBURG, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the second quarter ended June 30, 2024. "In the first half of the year, we made great progress to stabilize our financial position by strategically divesting assets, resolving several legacy issues, and securing operational cash flow and working capital improvements," said Joe Papa, president and CEO at Emergent. "As a result, we ex
8/6/24 5:01:00 PM ET
$EBS
Biotechnology: Pharmaceutical Preparations
Health Care

$EBS
Leadership Updates

Live Leadership Updates

Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
Executive Management Team appointments contribute to Emergent's transformation and beyond, including promotion of Jessica Perl to General Counsel and Corporate Secretary GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced the appointment of Simon Lowry, M.D., as chief medical officer, head of research and development, effective November 18. Dr. Lowry will be responsible for advancing Emergent's strategic scientific roadmap, and will oversee research and development, regulatory affairs, medical affairs, clinical an
11/4/24 7:30:00 AM ET
$EBS
Biotechnology: Pharmaceutical Preparations
Health Care
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic
Ongoing support of the ‘White House Challenge to Save Lives from Overdose' through workplace and public safety measuresOne-year mark of Ready to Rescue public awareness campaign to expand awareness, particularly among young adults and vulnerable communities20,000 additional doses of NARCAN® Nasal Spray to be donated to organizations in need GAITHERSBURG, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) remains committed to supporting widespread opioid emergency preparedness by expanding access to NARCAN® Nasal Spray and educating the public on how to respond to an opioid overdose. As opioid overdose fatalities have risen in the workplace in recent years,1 Emerg
10/8/24 5:32:28 PM ET
$EBS
Biotechnology: Pharmaceutical Preparations
Health Care
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings bro
9/4/24 8:00:00 AM ET
$CADL
$EBS
$MIST
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations

$EBS
Press Releases

Fastest customizable press release news feed in the world

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and Prevention GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that brincidofovir (brand name TEMBEXA®) will be included in a clinical trial conducted and sponsored by PANTHER, under the leadership of the Africa Centres for Disease Control and Prevention (Africa CDC), as part of the ‘MpOx Study in Africa' (MOSA). The study will evaluate the safety and efficacy of brincidofovir in treating mpox virus in a randomized double-blind placebo-controlled trial. "We applaud Africa CDC and PANTHER for the launch of the ‘MpOx Study in Africa' (MOSA)
11/6/24 4:49:03 PM ET
$EBS
Biotechnology: Pharmaceutical Preparations
Health Care
Emergent BioSolutions Reports Third Quarter 2024 Financial Results
Third Quarter 2024 Total Revenues of $293.8 million, increase of 9% versus prior yearThird Quarter 2024 Net Income of $114.8 million, increase of 144% versus prior yearThird Quarter 2024 Adjusted EBITDA of $105.3 million, increase of 432% versus prior yearRaises FY 2024 guidance GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the third quarter ended September 30, 2024. "Through disciplined execution and steady, measurable progress, Emergent's financial position is the strongest it has been since 2021 as evidenced by our favorable third-quarter results," said CEO Joe Papa. "We have successfully improved effici
11/6/24 4:05:00 PM ET
$EBS
Biotechnology: Pharmaceutical Preparations
Health Care
Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
Executive Management Team appointments contribute to Emergent's transformation and beyond, including promotion of Jessica Perl to General Counsel and Corporate Secretary GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced the appointment of Simon Lowry, M.D., as chief medical officer, head of research and development, effective November 18. Dr. Lowry will be responsible for advancing Emergent's strategic scientific roadmap, and will oversee research and development, regulatory affairs, medical affairs, clinical an
11/4/24 7:30:00 AM ET
$EBS
Biotechnology: Pharmaceutical Preparations
Health Care

Emergent BioSolutions Announces Shelf-Life Extension For NARCAN Nasal Spray In Canada From 36-Months To 48-Months

Chat with this insight

Recent Analyst Ratings for $EBS

$EBS Market Insights

Live Market Insights